Background
Considerable public attention and patient anxiety during the past decade have focused on the possible link between fertility drugs and ovarian cancer risk. Studies suggested that women who took fertility drugs, yet did not become pregnant, as well as women with longer durations of fertility drug exposure, are at substantially elevated risk of ovarian cancer.
⚠️ Key Concern
The question of whether ovulation-inducing agents increase cancer risk remains one of the most debated issues in reproductive medicine. This article reviews the current evidence, the proposed biological mechanisms, and presents real clinical cases from our practice.
Types of Ovulation-Inducing Medications
Group 1: Clomiphene Citrate (Clomid / Serophene)
Clomiphene citrate stimulates the pituitary gland to secrete the hormones LH and FSH, which in turn stimulate the ovaries. It is not a natural compound — it is a relative of tamoxifen and DES (diethylstilboestrol). This non-hormonal classification is clinically relevant when considering its potential oncological effects.
Group 2: Gonadotrophins & GnRH Analogues
The second group of ovulation-inducing medications are naturally occurring compounds found in the body. These include:
- Human menopausal gonadotrophins (hMG) — brand names Pergonal and Metrodin — which directly stimulate the ovary without going through the pituitary gland
- GnRH analogues (Factrel, LutrePulse) — which stimulate the pituitary to secrete LH and FSH, which then stimulate the ovaries
Proposed Biological Mechanisms
Several biological mechanisms have been proposed to explain how ovulation-inducing agents might increase cancer risk:
- Repeated ovulations disrupt the ovarian surface, potentially leading to malignant transformation — the "incessant ovulation" hypothesis
- Persistent stimulation of the ovary by pituitary hormones (LH and FSH) may have a direct carcinogenic effect, or may act through increased concentration of oestrogen caused by ovarian stimulation
- Processing of chemical carcinogens in the local ovarian environment may be altered by the hormonal milieu created by these medications
Evidence Base: What the Studies Suggest
A possible association between ovulation-inducing agents and an increased risk of cancer has been suggested by several lines of evidence:
- The theoretical possibility that any medication increasing ovarian activity could result in increased cancer risk
- Isolated case reports of individual women who took ovulation-inducing medications and subsequently developed ovarian cancer
- Retrospective case-controlled studies — these analyses showed that more women who developed ovarian cancer had taken "fertility medications" than would be expected compared to control groups
📋 Key Observations from Clinical Practice
- Hyperstimulation can cause damage to the ovarian surface epithelium
- Women who underwent indiscriminate use of ovulation-inducing agents appear to carry higher risk
- Women who underwent ovulation induction but never conceived may represent a particularly vulnerable subgroup
Case Study 1: A Young Nulliparous Woman with Epithelial Ovarian Cancer
🏥 Clinical Presentation
Age: 23 years | Status: Asymptomatic, married 3 years
The patient presented with infertility. Hormonal profile, ultrasound, and hysterosalpingography (HSG) were all normal. She underwent 2 cycles of IUI with ovulation induction, receiving Tab Siphene and injection FSH and HCG for two cycles.
🔬 Investigations
- On examination: no evidence of pelvic mass
- CA-125: 58 IU/L
- CT scan: Simple cyst in right ovary (29×26 mm) with no evidence of residual disease
- Uterus, left ovary, pelvic and para-aortic nodes, omentum, bowels, liver, spleen — all normal
⚕️ Surgical Findings & Histology
Laparoscopy and biopsy were performed. Histopathology revealed: Well-differentiated adenocarcinoma arising in right ovary, measuring 3.5×3.5×1 cm. Capsule intact. Peritoneal biopsies, cytology, omentum and nodes were all negative.
Surgical pathological stage: Stage Ic
🩺 Management Dilemma: Fertility Preservation vs. Standard Surgery
Standard staging laparotomy with TAH + BSO + bilateral pelvic lymph node dissection + omentectomy was recommended and explained to the patient.
However, fertility preservation in epithelial ovarian cancer is limited to Stage Ia, well-differentiated Grade I disease. The patient, at Stage Ic, was not an ideal candidate — yet she refused hysterectomy and bilateral oophorectomy and insisted on fertility-preserving surgery.
After a thorough review of the literature (only 2 published cases of fertility-preserving surgery in Stage Ic at the time) and with full informed consent, conservative surgery was performed.
📊 Outcome
Postoperatively, the patient received 3 cycles of Taxol and Carboplatin. Last CT scan (March 2007) showed no evidence of disease. Disease-free interval: 2 years at time of reporting.
Case Study 2: Endometrial Cancer in a 29-Year-Old with Infertility History
🏥 Clinical Presentation
Age: 29 years | Referred: 13th November 2003, as a case of carcinoma endometrium
Complaint of continuous per vaginum bleeding for 3 months. Endometrial aspiration report: well-differentiated adenocarcinoma, Grade 2. The patient had an active marriage of 6 years with a history of irregular menstrual periods and previous infertility treatment.
🔬 Examination Findings
- General: obese, short stature, hirsutism — pointing to possible PCOS background
- Vaginal examination: uterus enlarged, 12-week size
- P/R: both parametria free and smooth
- D&C: moderately differentiated adenocarcinoma of endometrioid type
⚕️ Surgery & Histopathology
Total abdominal hysterectomy with bilateral salpingo-oophorectomy, peritoneal cytology, bilateral pelvic lymph node sampling, and infracolic omental sampling were performed.
Histopathology revealed tumour measuring 3×1.5×0.7 cm and 1.5×1×0.6 cm in the anterior and posterior walls, showing superficial myometrial invasion (4 mm). Both ovaries showed multiple follicular cysts in the cortex with stromal proliferation in the medulla — consistent with polycystic ovarian pathology. Lymph nodes and omentum were all negative.
Final staging: Stage IB, Grade 2
📊 Outcome
Postoperative radiotherapy: Teletherapy (50 Gray / 25 fractions) followed by Brachytherapy (6.5 Gray at 5 mm). No radiotherapy-induced complications. Patient remains disease-free on regular follow-up.
Case Study 3: Cervical Cancer Following Infertility Treatment
🏥 Clinical Presentation
Age: 30 years | Nulligravida
Presented with white discharge and intermenstrual bleeding for 2–3 months. Past history of infertility treatment. Menstrual history: regular.
EUA with cervical biopsy: Stage Ib, moderately differentiated squamous cell carcinoma. Wertheim's hysterectomy with bilateral lymph node dissection performed on 5 June 2009.
🔬 Histopathology
Moderately differentiated squamous cell carcinoma (2.5 cm), infiltrating more than half the thickness of the cervix. Absent lymphovascular invasion. Pelvic lymph nodes and vaginal margins free, but microscopic involvement of the parametrium.
Final staging: Squamous cell carcinoma cervix, Stage IIb. Postoperative radiotherapy (XRT + ICR) completed August 2009. Patient asymptomatic on continuous follow-up.
Ovarian Cancer Risk: What the Data Shows
Fertility drugs are often identified as a risk factor for ovarian cancer. An evaluation of previous studies found that infertile women who used fertility drugs but never became pregnant had a significantly increased risk of ovarian cancer compared with women with no history of infertility.
The most recently published landmark study was a multicenter retrospective cohort conducted in 5 US centres. This study — initiated from medical records — followed 12,193 infertile women for a median of 18.8 years. The cohort study which detected 39 cases of endometrial cancer among clomiphene citrate users found a non-significant increase in relative risk (RR = 1.79, CI 0.9–3.4). Importantly, however, the data were primarily based on a comparison of fertility drug users with the general population — not with infertile women who did not use drugs — making interpretation difficult.
📊 The Whittemore Study (1992)
The Collaborative Ovarian Cancer Group (Whittemore et al., 1992) reported that infertile women using fertility drugs had almost three times the risk (RR = 2.8, 95% CI 1.3 to 6.1) for invasive epithelial ovarian cancer. This publication heightened awareness — and patient anxiety — around fertility medication use.
A study encompassing all 12,193 infertile women in five US fertility centres showed that the increase in risk of ovarian cancer was similar for women who received fertility drugs and those who did not — suggesting that infertility itself, not just the drugs, may be the primary driver of elevated risk.
Borderline Ovarian Tumours: A Stronger Signal
That ovulation-stimulating drugs might preferentially affect the risk of borderline ovarian tumours is suggested by several studies (Ness et al., 2002). Ovarian stimulation may induce growth in existing highly-differentiated indolent tumours. Alternatively, the findings could simply reflect more intensive medical surveillance among infertile women — leading to detection bias.
⚠️ Overall Assessment on Ovarian Cancer
Overall, the findings on ovarian cancer risk — particularly invasive epithelial and non-epithelial types — are reassuring. However, a stronger association between fertility drug use and borderline tumours of the ovary has been consistently observed (Mahdavi et al., 2006). The clinical relevance of this for the individual patient requires careful individualised risk discussion.
Endometrial Cancer Risk
An accurate assessment of the endometrial cancer risk associated with fertility drugs requires a randomised placebo-controlled trial in a uniform population of anovulatory women — a study that has not yet been conducted (Athuis et al., 2005).
Current evidence from the large multicenter US cohort suggests a non-significant trend towards increased risk with clomiphene citrate use. The confounding effect of PCOS — which is both a common reason for clomiphene use and an independent risk factor for endometrial cancer — makes it particularly difficult to isolate the drug effect.
Cervical Neoplasia: A Reduced Risk?
A case-cohort study from infertility clinics in Seattle examined the risk of cervical neoplasia associated with the use of ovulation-inducing agents, particularly clomiphene citrate.
| Finding | Result |
|---|---|
| Women in cohort who developed in situ or invasive cervical cancer | 36 cases |
| Expected cases based on general population rates | 67.8 cases |
| Standardised incidence ratio (SIR) | 0.5 (95% CI 0.4–0.7) |
| Risk in clomiphene citrate users vs. non-users | RR = 0.4 (95% CI 0.2–0.8) |
Infertile women — particularly those taking clomiphene citrate — showed a significantly reduced risk of cervical neoplasia compared to the general population.
📌 Conclusion on Cervical Risk
The hypothesis that use of antiestrogenic agents such as clomiphene citrate may reduce the risk of cervical neoplasia warrants testing in further studies. The antiestrogenic action of clomiphene at the cervical epithelium may be a plausible mechanism for this finding.
Breast Cancer Risk
Fifteen studies were identified in systematic reviews of IVF and breast cancer risk. Of these, 11 were cohort studies and 4 were case-control studies. None of the individual studies showed an overall significant association between IVF and breast cancer. Notably, one study showed that treatment with hCG significantly reduced the risk of breast cancer in women with a BMI below 27.5.
| Parameter | Value |
|---|---|
| Study cohort size (woman-years of follow-up) | 120,895 |
| Expected breast cancer cases | 115.2 |
| Observed breast cancer cases | 131 |
| Standardised incidence ratio (SIR) | 1.1 (95% CI 0.9–1.4) |
| Risk in clomiphene citrate users specifically | SIR = 1.4 (95% CI 1.0–1.8) — elevated |
Infertility and fertility drug use in general are not associated with increased breast cancer risk. However, clomiphene citrate users showed a modestly elevated risk.
⚠️ Important Caveat on Breast Cancer
Infertility and fertility drug use in general are not associated with increased breast cancer risk. However, for infertile women specifically treated with clomiphene citrate, breast cancer risk appears to be modestly elevated. This finding requires careful consideration in clinical counselling.
Study Limitations & Methodological Challenges
In general, epidemiological studies on fertility drug use and cancer risk are hampered by several methodological problems that limit the strength of conclusions:
- Small study size — leading to insufficient statistical power
- Short follow-up time — cancer may take decades to develop
- Low prevalence of infertility and fertility drug use in the general population
- Lack of information on confounding factors such as oral contraceptive use or family history of ovarian neoplasia
- Failure to analyse tumour types separately — invasive epithelial tumours, borderline tumours, and non-epithelial tumours should be analysed separately
- Selection bias in retrospective studies
- Wide confidence intervals in most reported estimates
- Lack of uniform etiology of infertility across study populations
- Temporal incompatibility between infertility treatment and licensing of modern fertility drugs
Conclusion & Future Directions
The relationship between ovulation induction and cancer risk remains nuanced. The current evidence does not support a clear, definitive causal link for most cancer types. However, the issue is not fully resolved, and several areas require continued investigation:
- Need for more thoughtful study planning — controlling for infertility diagnosis, BMI, PCOS status, and hormonal history
- International database linkage — to achieve the sample sizes needed for robust conclusions
- Improved long-term follow-up — given the latency of cancer development
- Continued investigation of fertility drugs and ovarian cancer among nulligravida women — this remains the highest-concern subgroup
🩺 Clinical Practice Implications
Until more definitive evidence is available, clinicians should: counsel patients thoroughly about the uncertain but possible risks; limit ovulation induction cycles to what is clinically necessary; ensure adequate follow-up; and remain vigilant for symptoms that may indicate early cancer in women with a history of prolonged fertility treatment.
Concerned About Your Fertility or Cancer Risk?
Get expert guidance from a specialist with experience in both reproductive medicine and oncological considerations.